KAI-9803, a more selective PKCδ inhibitor peptide derived from the δV1–1 portion of PKCδ was tested in clinical trials to treat myocardial infarction and was found not to reduce biomarkers of myocardial injury [[154], [155], [156]]. This evidence concerns the gene PRKCD and myocardial infarction.